dibenzo[b,g][1,8]naphthyridine | 257-95-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: dibenzo[b,g][1,8]naphthyridine
• 英文别名: dibenzo(b)1,8-naphthpyridine；bnp；quinolino[2,3-b]quinoline
• CAS: 257-95-4
• 化学式: C₁₆H₁₀N₂
• 分子量: 230.269
• InChiKey: FZYCVVVYQCUVQW-UHFFFAOYSA-N

物化性质

• 沸点：
  456.6±18.0 °C(Predicted)
• 密度：
  1.291±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  18
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  25.8
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  ammonium hexafluorophosphate 、 {NiCl2(phen)2} 、 dibenzo[b,g][1,8]naphthyridine 以 甲醇 为溶剂， 生成 (dibenzo(b)1,8-naphthpyridine)bis(1,10-phenanthroline)nickel(II) hexafluorophosphate
  参考文献：
  名称：

  Synthesis, DNA binding and cleavage studies of Ni(II) complexes with fused aromatic N-containing ligands

  摘要：

  The three Ni(II) complexes of fused aromatic N-containing ligands Such as [Ni(bnp)3](PF6)(2) (1), [Ni(phen)(2)(bnp)](PF6)(2) (2) and [Ni(bpy)(2)(bnp)](PF6)(2) (3) (where bnp=dibenzo(b)1,8-naphthpyridine, phen = 1,10-phenanthroline and bpy = bipyridine) were synthesized and structurally characterized. Elemental analysis, magnetic and spectroscopic data suggested octahedral geometry for all the complexes. Binding of these complexes with (ds)DNA were analyzed by absorption spectra, viscosity and thermal denaturation studies. Detailed analysis revealed that the metal complexes intercalates into the DNA base stack as intercalator. The oxidative cleavage activities of the complexes were studied with supercoiled (SC)pUC19 DNA by using gel electrophoresis. and the results show that complexes have potent nuclease activity. (c) 2008 Elsevier B.V. All rights reserved.

  DOI：

  10.1016/j.saa.2008.11.025
• 作为产物：
  描述：

  N-乙酰苯胺 在 三氯氧磷 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 生成 dibenzo[b,g][1,8]naphthyridine
  参考文献：
  名称：

  二苯并[b,g][1,8]萘啶的简单合成

  摘要：

  摘要 2-Chloro-3-formyl quinoline 及其衍生物在 DMF 中与苯胺反应得到二苯并[b,g][1,8]萘啶。

  DOI：

  10.1081/scc-120037914

文献信息

• [EN] RHENIUM COMPLEXES AND METHODS OF USE FOR TREATING CANCER<br/>[FR] COMPLEXES DE RHÉNIUM ET MÉTHODES D'UTILISATION POUR LE TRAITEMENT DU CANCER
  申请人：UNIV CORNELL

  公开号：WO2017223428A1

  公开（公告）日：2017-12-28

  A composition comprising the following structure: (formula I) wherein Re represents a rhenium ion having a +1 charge; (formula II) represents an uncharged bidentate bicyclic ligand bonded to the rhenium (Re) by two ring nitrogen (N) atoms; and L is a neutral ligand independently selected from CO and neutral phosphine molecules, wherein at least one of the L groups is a CO molecule; and X- represents a non-coordinating monovalent anion; wherein (formula II) is unsubstituted or substituted on any of its two rings, and said neutral phosphine molecule may or may not contain a phosphorus atom as a ring phosphorus atom; provided that, if (formula II) is unsubstituted, then one or two of said L groups are selected from said neutral phosphine molecules, with the provision that at least one of the neutral phosphine molecules has a phosphorus atom as a ring phosphorus atom. Methods for treating cancer by administering the above complex are also disclosed.

  以下结构的组成物：(公式I)，其中Re代表一个带有+1电荷的铼离子；(公式II)代表一个未带电的双齿双环配体，通过两个环上的氮(N)原子与铼(Re)结合；L是独立选择的电中性配体，选自CO和电中性磷化氢分子，其中至少一个L基团是CO分子；X-代表一个非配位的单价阴离子；(公式II)未取代或在其任一双环上进行取代，并且所说的电中性磷化氢分子可能含有也可能不含有作为环磷原子的磷原子；条件是，如果(公式II)未取代，则所说的L基团中有一个或两个选自所说的电中性磷化氢分子，并且至少有一个电中性磷化氢分子具有作为环磷原子的磷原子。还公开了通过施用上述复合物来治疗癌症的方法。
• [EN] RHENIUM COMPLEXES AND METHODS OF USE FOR TREATING CANCER<br/>[FR] COMPLEXES DE RHÉNIUM ET LEURS PROCÉDÉS D'UTILISATION POUR LE TRAITEMENT DU CANCER
  申请人：UNIV CORNELL

  公开号：WO2020037166A1

  公开（公告）日：2020-02-20

  A composition comprising the following structure: (1) wherein Re represents a rhenium ion having a +1 charge; (I) represents an uncharged bidentate ligand containing at least one ring containing a ring nitrogen atom bound to the rhenium (Re), and the bidentate ligand containing another nitrogen atom, either in a ring or not in a ring, bound to the rhenium (Re); and L1, L2, L3, and L4 are neutral ligands with at least one neutral ligand being an isonitrile ligand of the formula -CN-R, wherein R is an aliphatic or aromatic hydrocarbon group containing 1-20 carbon atoms; and X- represents a non-coordinating monovalent anion; wherein the bidentate ligand and R are optionally substituted by one or more groups selected from (i)-(xi) as further discussed above. Methods for treating a condition that benefits from ER stress induction, such as cancer, by administering the above rhenium complex are also disclosed.

  一种化合物，包括以下结构：(1)其中Re代表+1电荷的一种铼离子；(I)代表一个不带电的双齿配体，其中至少含有一个含有环氮原子的环，并与铼(Re)结合，双齿配体还含有另一个氮原子，无论是在环中还是不在环中，与铼(Re)结合；L1、L2、L3和L4是中性配体，其中至少一个中性配体是具有公式-CN-R的异腈配体，其中R是含有1-20个碳原子的脂肪族或芳香族碳氢基团；X-代表一个非配位的单价阴离子；其中双齿配体和R可选地被一种或多种从(i)-(xi)中选择的基团取代，如上所述。还公开了通过给予上述铼配合物治疗从ER应激诱导中受益的疾病（如癌症）的方法。
• Rhenium complexes and methods of use for treating cancer
  申请人：CORNELL UNIVERSITY

  公开号：US10973849B2

  公开（公告）日：2021-04-13

  A composition comprising the following structure: (formula I) wherein Re represents a rhenium ion having a +1 charge; (formula II) represents an uncharged bidentate bicyclic ligand bonded to the rhenium (Re) by two ring nitrogen (N) atoms; and L is a neutral ligand independently selected from CO and neutral phosphine molecules, wherein at least one of the L groups is a CO molecule; and X− represents a non-coordinating monovalent anion; wherein (formula II) is unsubstituted or substituted on any of its two rings, and said neutral phosphine molecule may or may not contain a phosphorus atom as a ring phosphorus atom; provided that, if (formula II) is unsubstituted, then one or two of said L groups are selected from said neutral phosphine molecules, with the provision that at least one of the neutral phosphine molecules has a phosphorus atom as a ring phosphorus atom. Methods for treating cancer by administering the above complex are also disclosed.

  一种由以下结构组成的组合物：(式 I) 其中 Re 代表具有 +1 电荷的铼离子；(式 II) 代表通过两个环氮 (N) 原子与铼 (Re) 键合的无电荷双齿双环配体；以及 L 是独立选自 CO 和中性膦分子的中性配体，其中至少一个 L 基团是 CO 分子；以及 X- 代表非配位一价阴离子；其中(式 II)在其两个环的任何一个上未被取代或被取代，所述中性膦分子可以含有或不含有作为环磷原子的磷原子；条件是，如果(式 II)未被取代，则所述 L 基团中的一个或两个选自所述中性膦分子，并规定至少一个中性膦分子具有作为环磷原子的磷原子。还公开了通过施用上述复合物治疗癌症的方法。
• Organic light-emitting diode devices with improved operational stability
  申请人：Eastman Kodak Company

  公开号：US20040076853A1

  公开（公告）日：2004-04-22

  An organic light-emitting device includes a substrate, an anode and a cathode disposed over the substrate, and a luminescent layer disposed between the anode and the cathode wherein the luminescent layer includes a host and at least one dopant. The host of the luminescent layer is selected to include a solid organic material comprising a mixture of at least two components, one of which is capable of forming both monomer state and an aggregate state.

  一种有机发光器件包括基板、设置在基板上的阳极和阴极，以及设置在阳极和阴极之间的发光层，其中发光层包括宿主和至少一种掺杂剂。发光层的宿主被选择为包括固体有机材料，该材料由至少两种成分的混合物组成，其中一种成分能够形成单体态和集合态。
• RHENIUM COMPLEXES AND METHODS OF USE FOR TREATING CANCER
  申请人：CORNELL UNIVERSITY

  公开号：US20190175645A1

  公开（公告）日：2019-06-13

  A composition comprising the following structure: (formula I) wherein Re represents a rhenium ion having a +1 charge; (formula II) represents an uncharged bidentate bicyclic ligand bonded to the rhenium (Re) by two ring nitrogen (N) atoms; and L is a neutral ligand independently selected from CO and neutral phosphine molecules, wherein at least one of the L groups is a CO molecule; and X − represents a non-coordinating monovalent anion; wherein (formula II) is unsubstituted or substituted on any of its two rings, and said neutral phosphine molecule may or may not contain a phosphorus atom as a ring phosphorus atom; provided that, if (formula II) is unsubstituted, then one or two of said L groups are selected from said neutral phosphine molecules, with the provision that at least one of the neutral phosphine molecules has a phosphorus atom as a ring phosphorus atom. Methods for treating cancer by administering the above complex are also disclosed.